Why Adicet Bio, Inc.’s (ACET) Stock Is Down 5.68%
As of Friday, July 31, Adicet Bio, Inc.’s ACET share price has dipped by 5.68%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company’s lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Commentary & Analysis
Why Adicet Bio, Inc.’s (ACET) Stock Is Up 5.66%
As of Thursday, July 30, Adicet Bio, Inc.’s ACET share price has surged by 5.66%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Adicet Bio, Inc.’s (ACET) Stock Is Down 5.58%
As of Friday, July 24, Adicet Bio, Inc.’s ACET share price has dipped by 5.58%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Adicet Bio, Inc.’s (ACET) Stock Is Up 6.20%
As of Tuesday, July 14, Adicet Bio, Inc.’s ACET share price has surged by 6.20%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Adicet Bio, Inc.’s (ACET) Stock Is Up 5.52%
As of Wednesday, July 08, Adicet Bio, Inc.’s ACET share price has surged by 5.52%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | ACET | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $95.7 | $252.6 | 21% |
|
| Shares Out (Mil) | 10.7 | 52.3 | 21% |
|
| Institutional Ownership | 97.9% | 92.1% | 76% |
|
| Float (Mil) | 7.4 | 40.2 | 16% |
|
| Beta | 1.59 | 0.95 | 84% |
|
| Avg Daily Volume (000s) | 90 | 455 | 35% |
|
| Price Change (52-week) |
(19.1%) | 52.9% | 31% |
|
| Growth | ACET | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (26.1%) | (9.9%) | 16% |
|
| EPS (5yr) | 26.7% | 16.0% | 77 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.1%) | (15.6%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 5 | 4 | |
| Current EPS | ($1.638) | ($8.800) | ($3.488) | |
| Month Ago EPS | ($1.638) | ($8.868) | ($4.192) | |
| # Rev Up | 1 | 2 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($2.160) | ($9.744) | ($3.355) | |
| Year/Year Chg | (13.1%) | (48.1%) | (111.6%) | |
| Financials | ACET | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($109) | ($43) | 10% |
|
| EPS (TTM) | ($13.346) | ($1.600) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($91) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $8 | $5 | 56% |
|
| Long-Term Debt (Q1) (Mil) | $11 | $5 | 29% |
|
| Enterprise Value (Q1) (Mil) | ($39) | $180 | 1% |
|
| Valuation | ACET | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.70 | 2.56 | 14% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ACET | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (60.4%) | (49.8%) | 10% |
|
| ROE | (72.2%) | (55.5%) | 12% |
|
| Liabilities to Assets | 17.3% | 30.3% | 11% |
|
| F-Score | 1 | 3 | 1% |
|
Adicet Bio, Inc. did not pass any screens on 7/31/2026.
